Bristol-Myers Squibb to acquire Mirati in a $4.8 billion deal

 Bristol-Myers Squibb is set to acquire cancer drugmaker Mirati Therapeutics for $58 per share in cash, representing $4.8 billion equity value.

Bristol-Myers Squibb will finance the transaction with a combination of cash and debt.

The transaction is expected to be dilutive to Bristol-Myers Squibb's non-GAAP earnings per share by approximately 35 cents per share in the first 12 months after the transaction closes.

https://finance.yahoo.com/news/1-bristol-myers-squibb-acquire-215410059.html